GPN clinical supervision session

Type 2 Diabetes case studies

Type 2 Diabetes Case studies

Welcome and introductions

Plan for today's session

Group discussion and learning from real patient cases

The names and pictures used are fictional- no patient identifiable data

GPN clinical supervision session 19/10/2022

Mavis

89-year-old lady who is being reviewed by GP for exacerbation of her COPD

Currently semi-conscious

Cared for in a nursing home

Daughter lives 80 miles away

Medical notes record that a DNAR is in place

Advanced directive signed in 2017- would prefer to die in the residential home if she becomes seriously ill



Current medical history

Type 2 diabetes

On NovoMix 30 BD- 8units AM 4units PM and Sitagliptin

50 mgs OD

Partially sighted

Chronic obstructive pulmonary disease

Ischaemic heart disease

Peripheral neuropathy

Severe dementia (Alzheimer's)



Clinical data

Respiration rate 28
Heart rate, 83
BP 131/62
Temp 37.2 centigrade
Capillary blood glucose 6.6 mmol/L @ 1500 hours
HbA1c 47 mmol/mol
eGFR 28mls/min



Group discussion

Please review this case and develop a diabetes management plan for Mavis considering her holistic needs and choices



Factors to consider

GP review - what is the plan and outcome of that?

How do we know if Mavis is entering the end-of-life phase?

What are her wishes and how should we respect them?

What symptoms and problems should we be aiming to minimise?

How do we tailor glucose-lowering therapy and minimise diabetes-related adverse treatment effects?



Factors to consider- continued

Relax glycaemic targets?

Insulin requirements – reduce/switch/stop?
Oral medications- reduce/switch/stop?
semi-conscious so unsafe swallow?

Blood glucose testing options?

CBG/flash monitoring/no testing?

Other important interventions?

Skincare, pain-control and hydration, maintain comfort and dignity



Suggested management plan

Revised blood glucose targets - aim for glucose levels between 6 mmol and 15 mmol/L

Keep blood glucose monitoring to once daily or use flash monitoring

Oral medication withdrawal- stop gliptin

Insulin requirements – stop or switch to basal and reduce

Keep Mavis comfortable, provide skin protection advice, minimise complications and symptoms of dehydration

GPN clinical supervision session 19/10/2022

Guidelines for EOL diabetes care



For Healthcare Professionals:

END OF LIFE GUIDANCE FOR DIABETES CARE

Endorsed by


November 2021












Contents- Trend Diabetes, EOL document

Update on diabetes oral therapies
Updated insulin recommendations to
include newer insulin treatments

- Care home residents
- Cancer
- Renal disease
- Frailty
- Steroid use
- COVID-19

- Enteral feeding
- Dementia
- Provided more information on:
- An advance decision
- An advance statement
- Emergency health care

Medicines management (Trend diabetes)



General guidance-Insulin

Doses may need to change if renal function declines

Hypoglycaemia risk will need to be reassessed with changes in eating patterns

A change of insulin regimen may be needed to match changes in "activity" levels and appetite

Insulin can often be reduced significantly or stopped in type 2 diabetes as appetite diminishes

Do not stop insulin completely in people with Type 1 diabetes

Usually maintain on an appropriate dose of basal once daily insulin

GPN clinical supervision session 19/10/2022

53-year-old South Asian lady
Diagnosis T2DM 2011
Started insulin 2 years ago
Strong family history of CVD and T2DM

HbA1c 76mmol/mol
BMI 27 kg/m2
BP 132/69
TC 4mmols, LDL 1.8mmols
eGFR 87mL/min/1.73m2



Current medication:

Metformin - 500mg twice daily Linagiptin 5mgs once daily Atorvastatin – 40mg once daily Humulin I - 68 units at night

Sitaben lives with her extended family unit Faith is an important part of her life Daily routine revolves around the kitchen- cooks a traditional South Asian Diet

Three meals per day with smaller between meal food at the temple



Husband and mother have T2DM Husband- MI and has diabetic retinopathy Mother insulin-dependent for many years, taking basal insulin

Sitaben has strong beliefs around medication

Has tried SU, SGLT2i and GLP1RA and stopped these soon after starting

Cites multiple side-effects

Does not wish to try these again

Recent discussion around an insulin regimen change

Has come to see you today to discuss this



Latest Self-Monitoring Blood Glucose readings:

Fasting Blood Glucose: 8.5-13.4mmols/L (153-241mg/dL)

Pre-lunch: 9.9-12.6mmols/L (142 -226 mg/dL)

Pre-evening meal: 12.7-21.2mmols/L (228-381 mg/dL)

Post evening meal: 9.9-19.1mmols/L (178 – 343 mg/dL)




Group discussion

Sitaben is very anxious about her diabetes and the health consequences of prolonged poor control.

Please discuss the clinical problems and sub-problems contributing to her poor glycaemic control.

Consider the treatment options for insulin management for Sitaben. Consider how you would address her concerns.







GPN clinical supervision session 19/10/2022

19

Suggested management plan

A culturally adapted and individualised lifestyle education and support plan

Carbohydrate awareness and meal planning

Planning for festivals and occasions

Movement and activity advice

Diabetes education

Well-being support

Check and optimise injection technique Intensify the insulin regimen



Insulin intensification options






Figure 3: Potential insulin intensification options

What happened?

Switched to basal-plus regimen, using Toujeo U300 + Novorapid.

Made one change at a time

Switched the basal insulin first

Added prandial insulin starting with 4units added to meal with highest postprandial excursion



Appointment 1- SWITCH TO TOUJEO
Appointment 2- FOUR days after appointment 1 ADD IN PRANDIAL INSULIN
Appointment 3- THREE to FOUR days after appointment 2 TITRATION of prandial insulin

- Demonstration of Doublestar pen
- •Stop HUMULIN I
- •Start 68 units Toujeo at bedtime
- •1:1 switch in line with SmPC guidance for Toujeo (35)
- •Request blood glucsose readings for next appointment
- Review BG trendsDemonstration of A
 - Demonstration of Apidra Solostar pen device
 - Prescription for Apidra Solostar pen, 4 units added to meal with largest postprandial meal pattern (42)
 - Explain the timing of injection. 15-20min before food has been shown to reduce PPG levels by approx. 30%, with less hypoglycaemia, when compared to injecting immediately before a meal (43)
- Agree realistic initial FBG and Premeal target ranges
- •One change at a time, so titrate up prandial insulin
- •If three day average BG is above the top number in the range, increase insulin by 2units
- Provide written titration plan and arrange follow up telephone appointments every 3-4 days to support the titration.

Review appointment 4 -TWO weeks after appointment 3

- •Review progress with titration and lifestyle choices
- Reassess FBG target and adjust insulin if necessary
- •Reassess Pre-meal BG target
- Hypoglycaeamia and illness advice

Review appointment 5 -TWO weeks after apointment 4

- •Assess injection sites and technique
- •Review of lifestyle support
- Consider adjusting Blood glucose target ranges downwards if realistic and acheivable.

Three month review appointment

- •Hba1c, BMI, urine ACR, foot check, Lipid profile and Blood pressure
- Medication review
- •Work towards long term ideal fasting and pre-meal BG target of 4-7mmol/l

Phillip

59-year-old gentleman
T2DM for 12 years
On insulin past 18months
Sales representative

HbA1c 65mmol/mol
BMI 28 (26 when insulin initiated)
eGFR trend over three years: 58, 56
and 53mL/min/1.73m2
BP 134/89



Phillip

Current medication:

Insulatard 24units before bed Metformin 1g twice daily Gliclazide 80mg twice daily

Range of home tests:

Pre-breakfast: 7-9.8mmol/l

Pre-lunch: not tested

Pre-evening meal: 7.5-12.4mmol/l

Pre-bed: not tested



Case discussion

Phillip attends for his review appointment to discuss his latest results.

Discuss a suggested management plan

Discuss insulin titration options



Suggested plan

Revisit eating pattern and provide carbohydrate awareness

Set an individualised HbA1c target and blood glucose target range

Review oral medications and consider SGLT2inhibitor See individual SmPCs and BNF guidance for renal cut-offs Addition of SGLT2i for reno-protective and Cardio-protective benefits Addition may allow down-titration of gliclazide/insulin

Agree an "alarm blood glucose level" e.g., 5mmol/L. Start down-titration if blood glucose starts dropping below this level



Review of oral medications- What NICE 2022 guidance suggests

In Cardiovascular disease or high risk patients

"Take into account the person's current treatment regimen and preferences and make a shared decision about switching treatments or adding an SGLT2 inhibitor, as appropriate" (NICE 2022)

Cardiovascular outcome trials and other key trials influencing targeted treatment decisions

EMPA-REG for Emagliflozin
CANVAS trial for Canagliflozin
DECLARETIMI 58 study for Dapagliflozin

eatment

Suggested plan

If he had no success/side-effects from SGLT2inhibitor:

Weight 86kg, yet currently taking 24units insulin daily.

A typical total daily dose once stable on insulin is 0.5-1unit/kg

Start by "fixing the fasting first"

Encourage him to continue checking Fasting Blood Glucose (FBG)

Discuss option to self-titrate

Set a target FBG- 5.5-6.5mmo/L

Review mean FBG every 3-4 days and compare to target

Titrate in 2-4unit steps and repeat 3-4days until target reached

Repeat HbA1c in 3 months



Summary

Mavis- End of life care

Sitaben-Insulin intensification

Phillip- Insulin titration and medicines optimisation

^presentation Title

THANK YOU!

omar.seedat@nhs.net

